Alyssa Wozniak, PharmD, BCPS

home / authors / alyssa-wozniak-pharmd-bcps

Articles

Focus on Smoking Cessation During COVID-19: Review of Varenicline Pharmacogenomics

Focus on Smoking Cessation During COVID-19: Review of Varenicline Pharmacogenomics

Alyssa Wozniak, PharmD, BCPS;Jay Shah, PharmD Candidate;Simona Armenti, PharmD Candidate
October 21st 2020

Patients with current or former smoking status may be at an increased risk of severe illness due to COVID-19.

Read More

Lasmiditan For the Acute Treatment of Migraine: An Opportunity For Pharmacists

Lasmiditan For the Acute Treatment of Migraine: An Opportunity For Pharmacists

Alyssa Wozniak, PharmD, BCPS;Robyn Schieble, PharmD candidate;Zeerak Ansari, PharmD candidate;Samantha Rowland, Pharm D candidate;Hyungwon Kim, PharmD candidate
May 28th 2020

Despite triptan availability as a migraine-specific rescue, the global burden of migraine morbidity remains high.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD